Cargando…
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC) develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here we perform whole exome sequencing and gene expression analysis of matched primary breast tumours and bone metastasi...
Autores principales: | Montaudon, Elodie, Nikitorowicz-Buniak, Joanna, Sourd, Laura, Morisset, Ludivine, El Botty, Rania, Huguet, Léa, Dahmani, Ahmed, Painsec, Pierre, Nemati, Fariba, Vacher, Sophie, Chemlali, Walid, Masliah-Planchon, Julien, Château-Joubert, Sophie, Rega, Camilla, Leal, Mariana Ferreira, Simigdala, Nikiana, Pancholi, Sunil, Ribas, Ricardo, Nicolas, André, Meseure, Didier, Vincent-Salomon, Anne, Reyes, Cécile, Rapinat, Audrey, Gentien, David, Larcher, Thibaut, Bohec, Mylène, Baulande, Sylvain, Bernard, Virginie, Decaudin, Didier, Coussy, Florence, Le Romancer, Muriel, Dutertre, Guillaume, Tariq, Zakia, Cottu, Paul, Driouch, Keltouma, Bièche, Ivan, Martin, Lesley-Ann, Marangoni, Elisabetta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426966/ https://www.ncbi.nlm.nih.gov/pubmed/32792481 http://dx.doi.org/10.1038/s41467-020-17697-1 |
Ejemplares similares
-
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers
por: El-Botty, Rania, et al.
Publicado: (2023) -
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
por: Pancholi, Sunil, et al.
Publicado: (2020) -
HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
por: El‐Botty, Rania, et al.
Publicado: (2023) -
Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation
por: Guest, Stephanie K., et al.
Publicado: (2016) -
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease
por: Simigdala, Nikiana, et al.
Publicado: (2018)